Painchek (ASX:PCK) Net Loan


ASX:PCK Painchek Ltd ASX:PCK
50 GF Score
Price A$0.11
GF Value A$0.40
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Painchek Net Loan?

Net Loan only applies to banks and insurance companies.

ASX:PCK
50GF Score
Painchek Ltd ASX:PCK
Net Loan is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Painchek (ASX:PCK) Overvalued in 2026?

Based on GuruFocus' analysis, Painchek stock appears to be undervalued. The current stock price of A$0.11 is trading 72.5% below its estimated GF Value™ of A$0.40. GuruFocus considers Painchek to be Possible Value Trap.

Key valuation signals for ASX:PCK:

  • Net Loan:
  • GF Value™: A$0.40 vs. price of A$0.11 (72.5% below fair value)
  • GF Score™: 50/100 with 3 warning signs

No single metric tells the full story. See the ASX:PCK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Painchek Business Description

Address 35 Lime Street, Suite 401, Sydney, NSW, AUS, 2000
Painchek Ltd is engaged in the development and commercialization of mobile medical device applications that provide pain assessment for individuals who are unable to communicate pain with carers. It operates in one segment, namely the sale of its pain assessment solutions. Its geographic segments include Australia, the United Kingdom, and Other countries, of which it generates the majority of its revenue from Australia.
50GF Score

Get the complete analysis for ASX:PCK

Net Loan is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.11
Price
A$0.40
GF Value